Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis

Bioorganic and Medicinal Chemistry

Volumn 20, Issue 6, 2012, Pages 2131-2140

  Arns, Steve ^a   Gibe, Romelo ^a   Moreau, Anne ^a   Monzur Morshed, M ^a   Young, Robert N ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Agonist; Alendronic acid; Anabolic; Bone targeting; Conjugates; Dual action; EP4 receptor; Osteoporosis; Prostaglandin E 2; Radiolabelled; Slow release

Indexed keywords

3 BENZYL 2H BENZO[E][1,3]OXAZINE 2,4(3H) DIONE; 4 [[[5 [6 [2 (4,4 DIFLUORO 3 HYDROXY 4 PHENYLBUT 1 ENYL) 5 OXOPYRROLIDIN 1 YL]HEXYL] 2H TETRAZOL 2 YL]METHOXY]CARBONYLAMINO] 1 HYDROXYBUTANE 1,1 DIYLDIPHOSPHORIC ACID; 4 HYDROXYPHENYLACETIC ACID; 4[1 (7 ETHOXY 7 OXOPHEPTYL) 5 OXOPYRROLIDIN 2 YL] 1,1 DIFLUORO 1 PHENYLBUT 3 EN 2 YL 2 ACETOXYBENZOATE; 4[1 (7 ETHOXY 7 OXOPHEPTYL) 5 OXOPYRROLIDIN 2 YL] 1,1 DIFLUORO 1 PHENYLBUT 3 EN 2 YL 2 HYDROXYBENZOATE; 4[1 (7 ETHOXY 7 OXOPHEPTYL) 5 OXOPYRROLIDIN 2 YL] 1,1 DIFLUORO 1 PHENYLBUT 3 EN 2 YL [(4 NITROPHENOXY)CARBONYL]BENZOATE; 4[[4 [1 (7 ETHOXY 7 OXOHEPTYL) 5 OXOPYRROLIDIN 2 YL] 1,1 DIFLUORO 1 PHENYLBUT 3 EN 2 YLOXY]CARBONYLAMINO]1 HYDROXYBUTANE 1,1 DIPHOSPHORIC ACID; [4 [[[4 [2 [[4[1 (ETHOXY 7 OXOHEPTYL) 5 OXOPYRROLIDIN 2 YL] 1,1 DIFLUORO 1 PHENYLBUT 3 EN 2 YL]OXY] 2 OXOETHYL]PHENOXY]CARBONYL]AMINO] 1 HYDROXYBUTANE 1,1 DIYL]DIPHOSPHONIC ACID; [5[6[2 (4,4 DIFLUORO 3 HYDROXY 4 PHENYLBUT 1 ENYL) 5 OXOPYRROLIDIN 1 YL]HEXYL] 2 H TETRAZOL 2 YL]METHYL 4 NITROPHENYLCARBONATE; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETHYL 7 [2 [3 [2 [4 (TERT BUTYLDIMETHYLSILYLOXY)PHENYL]ACETOXY] 4,4 DIFLUORO 4 PHENYLBUT 1 ENYL] 5 OXOPYRROLIDIN 1 YL]HEPTANOATE; ETHYL 7 [2 [4,4 DIFLUORO 3 [(4 NITROPHENOXY)CARBONYLOXY] 4 PHENYLBUT 1 ENYL] 5 OXOPYRROLIDIN 1 YL]HEPTANOATE; ETHYL 7 [2 [4,4 DIFLUORO 3 [2 (4 HYDROXYPHENYL)ACETOXY] 4 PHENYLBUT 1 ENYL] 5 OXOPYRROLIDIN 1 YL]HEPTANOATE; ETHYL 7 [[2 [[4,4 DIFLUORO 3 [2 (4 NITROPHENOXY)CARBONYLOXY]PHENYL]ACETOXY] 4 PHENYLBUT 1 ENYL] 5 OXOPYRROLIDIN 1 YL]HEPTANOATE; PRODRUG; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; IN VIVO STUDY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; RAT;

ALENDRONATE; ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DRUG DESIGN; FEMALE; OSTEOPOROSIS; PHENYLACETATES; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE;

RATTUS;

EID: 84857924218     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2012.01.024     Document Type: Article

References (18)

1. J.Y. Gauthier, N. Chauret, W. Cromlish, S. Desmarais, L.T. Duong, J.-P. Falgueyret, D.B. Kimmel, S. Lamontagne, S. Leger, T. LeRiche, C.S. Li, F. Masse, D.J. McKay, D.A. Nicoll-Griffith, R.M. Oballa, J.T. Palmer, M.D. Percival, D. Riendeau, J. Robichaud, G.A. Rodan, S.B. Rodan, C. Seto, M. Therien, V.-L. Troung, M.C. Venuti, G. Wesolowski, R.N. Young, R. Zamboni, and W.C. Black Bioorg. Med. Chem. Lett. 18 2008 923
2. J.L. Vahle, G.G. Long, G. Sandusky, M. Westmore, Y.L. Ma, and M. Sato Toxicol. Pathol. 32 2004 426
3. K. Ueno, D.B. Kimmel, D.M. Woodbury, P. Price, and L.A. Woodbury Bone 6 1985 79
4. W.S.S. Jee, H.Z. Ke, and X.J. Li J. Bone Mineral. 15 1991 33
5. R.W. Norrdin, W.S.S. Jee, and W.B. Hi Prost. Leuk. Essent Fatty Acids 41 1990 139
6. L. Gil, Y. Han, E.E. Opas, G.A. Rodin, R. Ruel, J.G. Seedor, P.C. Tyler, and R.N. Young Bioorg. Med. Chem. Lett. 7 1999 901
7. M. Machwate, S. Harada, C.T. Leu, G. Seedor, M. Labelle, M. Gallant, S. Hutchins, N. Lachance, N. Sawyer, D. Slipetz, K.M. Metters, S.B. Rodan, R. Young, and G.A. Rodan Mol. Pharmacol. 60 2001 36
8. H. Uludag Curr. Pharm. Des. 8 2002 1929
9. D. Heymann, B. Ory, F. Gouin, J.R. Green, and F. Rédini Trends Mol. Med. 10 2004 337 343
10. S. Ebner, B. Attali, and D. Shabat Bioorg. Med. Chem. Lett. 18 2008 816
11. X. Billot, R. N. Young, H. Han. 1,5-Disubstituted Pyrrolid-2-one Derivatives For Use As EP4 Receptor Agonists In The Treatment of Eye Diseases Such As Glaucoma. US Patent WO 03/103772. December 18, 2003.
12. R.N. Young, X. Billot, Y. Han, D.A. Slipetz, N. Chauret, M. Belley, K. Metters, M.-C. Mathieu, G.M. Grieg, D. Denis, and M. Girard Heterocycles 54 2004 437
13. T. Maruyama, M. Asada, T. Shiraishi, H. Yoshida, T. Maruyama, S. Ohuchida, H. Nakai, K. Kondo, and M. Toda Bioorg. Med. Chem. 10 2002 1743
14. M. Tanaka, A. Sakai, S. Uchida, S. Tanaka, M. Nagashima, T. Katayama, K. Yamaguchi, and T. Nakamura Bone 34 2004 940
15. X. Billot, A. Chateauneuf, N. Chauret, D. Denis, G. Greig, M.-C. Mathieu, K.M. Metters, D.M. Slipetz, and R.N. Young Bioorg. Med Chem Lett. 13 2003 1129
16. L.K. Gediya, A. Khandelwal, J. Patel, A. Belosay, G. Sabnis, J. Mehta, P. Purushottamachar, and V.C.O. Njar J. Med. Chem. 51 2008 3895
17. S. Arns, A. Moreau, and R.N. Young J. Labelled Comp. Rad. 53 2010 205
18. O. Brümmer, T.Z. Hoffman, D.-W. Chen, and K.D. Janda Chem. Comm. 4 2001 19